{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:59:25Z","timestamp":1788472765306,"version":"build-2803163510"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1097\/rhu.0b013e318204aab4","type":"journal-article","created":{"date-parts":[[2012,12,17]],"date-time":"2012-12-17T17:58:07Z","timestamp":1355767087000},"page":"7-13","source":"Crossref","is-referenced-by-count":111,"title":["Renal Function in Gout"],"prefix":"10.1097","volume":"17","author":[{"given":"Andrew","family":"Whelton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lhanoo","family":"Gunawardhana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210207","first-page":"215","article-title":"Hyperuricemia and gout: new insights into pathogenesis and treatment.","volume":"65","author":"Pillinger","year":"2007","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"R2-2-20210207","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1291\/hypres.24.691","article-title":"Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects.","volume":"24","author":"Iseki","year":"2001","journal-title":"Hypertens Res"},{"key":"R3-2-20210207","first-page":"66","article-title":"A preliminary investigation of the association between serum uric acid and impaired renal function.","volume":"32","author":"Chen","year":"2009","journal-title":"Chang Gung Med J"},{"key":"R4-2-20210207","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.semnephrol.2004.10.001","article-title":"Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease.","volume":"25","author":"Kang","year":"2005","journal-title":"Semin Nephrol"},{"key":"R5-2-20210207","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/rheumatology\/ken070","article-title":"Hyperuricaemia-where nephrology meets rheumatology.","volume":"47","author":"Avram","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"R6-2-20210207","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0272-6386(04)00934-5","article-title":"Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort.","volume":"44","author":"Iseki","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"R7-2-20210207","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1001\/archinte.161.9.1207","article-title":"Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994).","volume":"161","author":"Coresh","year":"2001","journal-title":"Arch Intern Med"},{"key":"R8-2-20210207","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/HJH.0b013e3282f29876","article-title":"Pathogenesis of essential hypertension: historical paradigms and modern insights.","volume":"26","author":"Johnson","year":"2008","journal-title":"J Hypertens"},{"key":"R9-2-20210207","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/01.HYP.0000254480.64564.b6","article-title":"Hyperuricemia and incidence of hypertension among men without metabolic syndrome.","volume":"49","author":"Krishnan","year":"2007","journal-title":"Hypertension"},{"key":"R10-2-20210207","first-page":"1466","article-title":"Serum uric acid is independently associated with hypertension in patients with rheumatoid arthritis.","volume":"46","author":"Panoulas","year":"2007","journal-title":"J Hum Hypertens"},{"key":"R11-2-20210207","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"R12-2-20210207","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine.","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"R13-2-20210207","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1681\/ASN.2004030208","article-title":"Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study.","volume":"16","author":"Domrongkitchaiporn","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R14-2-20210207","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1681\/ASN.2008010080","article-title":"Elevated uric acid increases the risk for kidney disease.","volume":"19","author":"Obermayr","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R15-2-20210207","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R16-2-20210207","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","article-title":"Gout medication treatment patterns and adherence to standards of care from a managed care perspective.","volume":"81","author":"Sarawate","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"R17-2-20210207","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.lfs.2004.10.031","article-title":"Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase\/xanthine dehydrogenase.","volume":"76","author":"Takano","year":"2005","journal-title":"Life Sci"},{"key":"R19-2-20210207","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1074\/jbc.M208307200","article-title":"An extremely potent inhibitor of xanthine oxidoreductase: crystal structure of the enzyme-inhibitor complex and mechanism of inhibition.","volume":"278","author":"Okamoto","year":"2003","journal-title":"J Biol Chem"},{"key":"R20-2-20210207","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout.","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"R21-2-20210207","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R23-2-20210207","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat for the treatment of hyperuricemia and gout.","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"R24-2-20210207","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1161\/hy1101.092839","article-title":"Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism.","volume":"38","author":"Mazzali","year":"2001","journal-title":"Hypertension"},{"key":"R25-2-20210207","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1097\/01.ASN.0000034910.58454.FD","article-title":"A role for uric acid in the progression of renal disease.","volume":"13","author":"Kang","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R26-2-20210207","doi-asserted-by":"crossref","first-page":"F991","DOI":"10.1152\/ajprenal.00283.2001","article-title":"Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism.","volume":"282","author":"Mazzali","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"key":"R27-2-20210207","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1097\/HJH.0b013e328303205d","article-title":"Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency.","volume":"26","author":"Eraranta","year":"2008","journal-title":"J Hypertens"},{"key":"R28-2-20210207","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1523-1755.2005.00074.x","article-title":"Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats.","volume":"67","author":"Sanchez-Lozada","year":"2005","journal-title":"Kidney Int"},{"key":"R29-2-20210207","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/ndt\/gfm783","article-title":"Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia.","volume":"23","author":"Sanchez-Lozada","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R30-2-20210207","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000127837","article-title":"Effect of febuxostat on the progression of renal disease in 5\/6 nephrectomy rats with and without hyperuricemia.","volume":"108","author":"Sanchez-Lozada","year":"2008","journal-title":"Nephron Physiol"},{"key":"R31-2-20210207","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/ard.41.1.59","article-title":"Allopurinol treatment and its effect on renal function in gout: a controlled study.","volume":"41","author":"Gibson","year":"1982","journal-title":"Ann Rheum Dis"},{"key":"R32-2-20210207","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s11255-007-9253-3","article-title":"Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions.","volume":"39","author":"Kanbay","year":"2007","journal-title":"Int Urol Nephrol"},{"key":"R33-2-20210207","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","article-title":"Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.","volume":"47","author":"Siu","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"R34-2-20210207","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/geronj\/31.2.155","article-title":"The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study.","volume":"31","author":"Rowe","year":"1976","journal-title":"J Gerontol"},{"key":"R35-2-20210207","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/art.20935","article-title":"Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.","volume":"52","author":"Becker","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R36-2-20210207","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","article-title":"Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.","volume":"48","author":"Schumacher","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R37-2-20210207","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","article-title":"Preliminary criteria for the classification of the acute arthritis of primary gout.","volume":"20","author":"Wallace","year":"1977","journal-title":"Arthritis Rheum"},{"key":"R38-2-20210207","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med"},{"key":"R39-2-20210207","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"R40-2-20210207","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/art.10792","article-title":"Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output.","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R41-2-20210207","doi-asserted-by":"crossref","first-page":"26834","DOI":"10.1074\/jbc.C800156200","article-title":"Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans.","volume":"283","author":"Anzai","year":"2008","journal-title":"J Biol Chem"},{"key":"R42-2-20210207","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1371\/journal.pmed.0050197","article-title":"SLC2A9 is a high-capacity urate transporter in humans.","volume":"5","author":"Caulfield","year":"2008","journal-title":"PLoS Med"},{"key":"R43-2-20210207","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/art.21499","article-title":"Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population.","volume":"54","author":"Graessler","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R44-2-20210207","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(08)61343-4","article-title":"Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study.","volume":"372","author":"Dehghan","year":"2008","journal-title":"Lancet"},{"key":"R45-2-20210207","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/ndt\/gfh584","article-title":"Uric acid correlates with the severity of histopathological parameters in IgA nephropathy.","volume":"20","author":"Myllymaki","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"R46-2-20210207","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1093\/ndt\/gfm790","article-title":"Predictors of new-onset decline in kidney function in a general middle-european population.","volume":"23","author":"Obermayr","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R47-2-20210207","doi-asserted-by":"crossref","first-page":"F1134","DOI":"10.1152\/ajprenal.00104.2008","article-title":"Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia.","volume":"295","author":"Sanchez-Lozada","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"R48-2-20210207","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1161\/CIRCULATIONAHA.106.651117","article-title":"High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid.","volume":"114","author":"George","year":"2006","journal-title":"Circulation"},{"key":"R49-2-20210207","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/art.1780341203","article-title":"Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout.","volume":"34","author":"McCarthy","year":"1991","journal-title":"Arthritis Rheum"},{"key":"R50-2-20210207","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R51-2-20210207","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1159\/000105142","article-title":"The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease.","volume":"27","author":"Talaat","year":"2007","journal-title":"Am J Nephrol"},{"key":"R52-2-20210207","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1023\/B:CARD.0000015855.02485.e3","article-title":"Cardiovascular drugs and serum uric acid.","volume":"17","author":"Reyes","year":"2003","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["JCR: Journal of Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RHU.0b013e318204aab4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:55:20Z","timestamp":1620971720000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00124743-201101000-00002"}},"subtitle":["Long-Term Treatment Effects of Febuxostat"],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/rhu.0b013e318204aab4","relation":{},"ISSN":["1076-1608"],"issn-type":[{"value":"1076-1608","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}